Monedero, PabloGea, AlfredoCastro Rebollo, PedroCandela Toha, Angel M.Hernández Sanz, María L.Arruti, EgoitzVillar, JesúsFerrando, CarlosCOVID-19 Spanish ICU Network2022-06-012022-06-012021-01-041364-8535https://hdl.handle.net/2445/186219Background: Critically ill patients with coronavirus disease 19 (COVID-19) have a high fatality rate likely due to a dysregulated immune response. Corticosteroids could attenuate this inappropriate response, although there are still some concerns regarding its use, timing, and dose. Methods: This is a nationwide, prospective, multicenter, observational, cohort study in critically ill adult patients with COVID-19 admitted into Intensive Care Units (ICU) in Spain from 12th March to 29th June 2020. Using a multivariable Cox model with inverse probability weighting, we compared relevant outcomes between patients treated with early corticosteroids (before or within the frst 48 h of ICU admission) with those who did not receive early corticosteroids (delayed group) or any corticosteroids at all (never group). Primary endpoint was ICU mortality. Secondary endpoints included 7-day mortality, ventilator-free days, and complications. Results: A total of 691 patients out of 882 (78.3%) received corticosteroid during their hospital stay. Patients treated with early-corticosteroids (n=485) had lower ICU mortality (30.3% vs. never 36.6% and delayed 44.2%) and lower 7-day mortality (7.2% vs. never 15.2%) compared to non-early treated patients. They also had higher number of ventilator-free days, less length of ICU stay, and less secondary infections than delayed treated patients. There were no diferences in medical complications between groups. Of note, early use of moderate-to-high doses was associated with better outcomes than low dose regimens. Conclusion: Early use of corticosteroids in critically ill patients with COVID-19 is associated with lower mortality than no or delayed use, and fewer complications than delayed use. Keywords: COVID-19, Intensive Care Unit, Corticosteroids, Critically ill patient, Cohort study, Outcomes, Ventilatorfree days, Mortality13 p.application/pdfengcc-by (c) Monedero, Pablo et al., 2021https://creativecommons.org/licenses/by/4.0/COVID-19Malalts en estat críticResposta immunitàriaInflamacióCorticosteroidesAssaigs clínicsMortalitatCOVID-19Critically illImmune responseInflammationAdrenocortical hormonesClinical trialsMortalityinfo:eu-repo/semantics/article7189042022-06-01info:eu-repo/semantics/openAccess33397463